Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay
Launched by ANCHORDX MEDICAL CO. LTD. US · Dec 6, 2022
Trial Information
Current as of February 05, 2025
Suspended
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Clinical Validation Group:
- • 1. 55 years or older, gender is not limited
- • 2. Suspected of bladder cancer and are scheduled for bladder biopsy or trans-uretheral resection of bladder tumor (TUBRT)
- • 3. Can receive standard of care, including urine cytology, cystoscopy, or surgery for bladder cancer diagnosis
- • 4. Can provide at least of 75 ml of urine (prior to cystoscopy or surgery)
- Exclusion Criteria:
- • 1. History of urinary cancer
- • 2. Neoadjuvant therapy
Trial Officials
Jianbing Fan, Ph.D
Study Director
AnchorDx Medical Co., Ltd.
About Anchordx Medical Co. Ltd. Us
Anchordx Medical Co., Ltd. US is a pioneering organization dedicated to advancing healthcare through innovative diagnostic solutions and clinical research. With a strong focus on precision medicine, the company develops cutting-edge technologies that enhance disease detection and patient management. Anchordx Medical is committed to conducting rigorous clinical trials that adhere to the highest ethical standards, aiming to improve patient outcomes and contribute to the scientific community. Through collaboration with healthcare professionals and researchers, the company strives to bring transformative medical advancements to market, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Little Rock, Arkansas, United States
Meridian, Idaho, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials